GlassScriptPhysician profile
Mark J Bernstein
NPI 1659384428
$1,112.85
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $187 · 2021: $55.41 · 2022: $137.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $283.55 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $191.19 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $125.00 | 2022 | |
| Allergan, INC. | $78.71 | 2019-2020 | |
| Shire North American Group INC | $74.85 | 2019 | |
| Jazz Pharmaceuticals INC. | $71.15 | 2019-2020 | |
| Abbvie INC. | $67.68 | 2021-2022 | |
| Neuronetics, INC. | $54.42 | 2019 | |
| Lundbeck LLC | $33.34 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $28.77 | 2019 | |
| Bausch Health US, LLC | $25.02 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.33 | 2019 | |
| Alfasigma USA, INC. | $15.06 | 2020 | |
| Tris Pharma INC | $14.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.89 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $11.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.